DailyIQ
|
Sector:HealthcareAll sectors
Last updatedjust now

COO·The Cooper Companies, Inc.

$54.25
-0.34 (-0.62%)
High
$55.24
Open
$54.59
Market Cap
10.58B
52W High
$90.00
Low
$53.92
P. Close
$54.25
P/E
18.55
52W Low
$49.49
Fwd P/E
11.63
DailyIQ Est.
$66.84
Inst. Ownership
41.8%
Short Interest
4.29%
Days to Cover
1.6
Technical Score (1D)
17
BEARISH
News Sentiment
64
BULLISH
COO is a momentum laggard on the 1D chart: a Technical Score of 17 with declining momentum and weak trend strength. The score ranks stocks against each other, so a reading this low says The Cooper Companies, Inc. has been one of the weaker performers in the universe, not that it is oversold. Sentiment at 64 is diverging from that weakness. $56.78 is the level a recovery would need to reclaim, and $51.32 is the next downside reference below $52.42. A bottom momentum rank reflects the prior year of trading, so it changes gradually even when the stock has a strong week. For near-term direction, price levels give the earlier read: a close back above $56.78 on real volume would be the first sign of repair, while a break of $52.42 keeps the bearish trend in charge.
LOW TARGET
$58 +6.9%
2 analysts
MEAN TARGET
$66 +21.3%
13 analysts
HIGH TARGET
$75 +38.3%
10 analysts
PRICE RANGE
$58.00 - $75.00
SB / B / H / S / SS
6/7/10/1/1
DAILYIQ EST.
$66.84 (+23.2%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NMS
Country
United States
Website
coopercos.com
Symbol
COO
Description
Cooper Companies, Inc. is a global medical device company primarily focused on two distinct segments: vision care and women's health. Through its CooperVision division, the company designs, manufactures, and distributes a comprehensive portfolio of contact lenses, addressing a range of vision impairments including astigmatism, presbyopia, and myopia. The CooperSurgical segment concentrates on fertility solutions, women's health devices, and related services, including hormone-free contraception and cryostorage options. Cooper Companies' products and services are marketed to a diverse network of distributors, healthcare professionals, and institutions, encompassing both independent and corporate entities. Founded in 1958, the company leverages its established presence and product diversity to serve the needs of eye care and women's health markets.
Bought (1Y)
14,701.015 shares
$799K
Sold (1Y)
0 shares
$0
Kurzius Lawrence Erik-
Buy10,000 shares2026-09-16
Keel Paul A-
Buy4,701.015 shares2026-09-11
Keel Paul A-
Award/Grant2,814 shares2026-07-01
View full insider trading history →
75/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
65.5%
Net Margin
9.2%
Revenue CAGR
8.3%
Current Ratio
1.89x
Debt / Equity
0.30x
Return on Equity
4.6%
View full financials →
Earnings Summary
Cooper Companies, Inc. is a global medical device firm with two primary segments: vision care through CooperVision and women’s health via CooperSurgical, offering contact lenses and fertility solutions. The company operates within the broader healthcare and medical instruments sector, serving a diverse network of distributors and healthcare professionals. In the most recent quarters, Cooper Companies posted EPS of $0.92 in Q4 2024, $0.96 in Q1 2025, $1.10 in Q2 2025, and $1.15 in Q3 2025, each beating analyst estimates and showing a steady upward trajectory; revenue rose from $964.7 million in Q4 2024 to $1.0653 billion in Q3 2025, a 10.5% YoY increase. The company has consistently outperformed expectations in the last four quarters, with EPS beats in all four periods and revenue growth maintained even when guidance remained flat. Historically, Cooper Companies has delivered double‑digit revenue growth while maintaining EPS beats, reflecting disciplined cost management and successful product launches. Recent news highlights a modest earnings beat forecast for Q3 2026, with guidance of $1.11 per share and $1.1 billion in revenue, and mentions potential divestiture of the CooperSurgical unit, which could unlock value. Key will be how the company translates recent product launches into tangible margin gains and whether the AI‑driven operational tools and HSA asset growth continue to support cost control and revenue expansion.

EPS

EstBeatMiss
$1.00$1.06$1.12$1.18$1.24Q2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$1.03 - -
Q3'26$1.12$1.15+2.7%
Q2'26$1.11$1.21+9.3%
Q1'26$1.04$1.10+5.7%
Q3'25$1.11$1.15+3.3%
Q2'25$1.07$1.10+3.0%

Revenue

EstBeatMiss
$1.0B$1.0B$1.1B$1.1B$1.1BQ2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$1.0B - -
Q3'26$1.1B$1.1B-3.9%
Q2'26$1.1B$1.1B+1.6%
Q1'26$1.0B$1.0B-1.2%
Q3'25 - $1.1B -
Q2'25 - $1.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COO Stock Snapshot

BEARISH17/100
$54.25−$0.34 (0.6%)
Market cap
10.58B
P/E ratio
18.6
Day range
$53.92 – $55.24
News sentiment
64/100 · Bullish
Analyst target
$65.80 (+21.3%)
Consensus
Hold · 25 analysts
52-week range+9.6% off low · -39.7% from high
$49.49$90.00
Price $54.25 DailyIQ Est. $66.84

The chart on COO has not stabilised: price is near its 52-week low and the trend is still down. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into COO?

RICH

At today's price, The Cooper Companies, Inc. needs to grow free cash flow about 14.1% a year for the next 10 years to justify its valuation at a 8.01% cost of capital. Over its actual history it has compounded free cash flow at 5.2% a year, so the market is asking for 8.9 percentage points above its own delivered rate. On that basis COO looks priced above what its own growth record supports.

Implied FCF growth
14.1%
Historical FCF CAGR
5.2%
Growth gap
+8.9 pts
Verdict
RICH
Discount rate (WACC)
8.01%
Beta
0.81

Behaviour On Record

What COO's own history says about today's numbers

Realized volatility (21d)
22.3% 27th pct
vs 200-day average
-22.6%
Up days (1y)
45%

The Cooper Companies, Inc. is currently running 22.3% annualised volatility over the last 21 sessions. Measured against COO's own 3 years of daily returns rather than a market-wide average, that is the 27th percentile — on the quiet side for this stock, against a typical reading of 26.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

Price sits -22.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 6th percentile — a narrower gap than it typically runs. Over the past year COO closed higher on 45% of sessions, and it is currently 1 session into a falling streak.

Overnight risk is measurable too: COO has opened more than 2% away from the prior close in 37 of 764 sessions (4.8% of the time), with the largest gaps running +6.6% and -3.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 4 dated reports on file, COO moved an average of 3.5% in the session after earnings, closing higher 2 of those 4 times, with a median move of +0.7% and a largest of -8.0%.

All figures computed from 765 daily closes between 2023-09-26 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against COO's own 3-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of COO's sector?

The Cooper Companies, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for COO?

CallsPuts

For The Cooper Companies, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.66), with at-the-money implied volatility around 40.6%. The options market is pricing roughly a ±3.4% move by that expiry — a range of about $52.27–$55.97.

Put/call ratio (2026-10-16)
0.66
ATM implied volatility
40.6%
Total open interest
4,506
Expected move by 2026-10-16
±3.4% ($52.27–$55.97)

Analyst Rating Changes

Are analysts turning bullish or bearish on COO?

Barclays most recently initiated coverage on The Cooper Companies, Inc. to Equal-Weight on Oct 7, 2026 with a price target of $60. Over the last 90 days, coverage has run 0 upgrades against 4 downgrades, a net bearish lean.

Latest action
Barclays — Equal-Weight
90-day upgrades
0
90-day downgrades
4
Net rating momentum
-4
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedEqual-Weight$60
Sep 15, 2026NeedhamReiteratedBuy$73
Sep 11, 2026MizuhoMaintainedOutperform$85 → $75
Sep 10, 2026William BlairDowngradeOutperform → Market Perform-
Sep 10, 2026Wells FargoMaintainedEqual-Weight$66 → $61
Sep 10, 2026StifelMaintainedBuy$85 → $70
Sep 10, 2026CitigroupMaintainedNeutral$80 → $60
Sep 10, 2026Piper SandlerDowngradeOverweight → Neutral$86 → $59
Sep 10, 2026JP MorganMaintainedNeutral$71 → $58
Sep 10, 2026UBSMaintainedNeutral$75 → $66
Sep 10, 2026B of A SecuritiesDowngradeBuy → Neutral$80 → $65
Sep 10, 2026BairdDowngradeOutperform → Neutral$85 → $61

Peers & ETF holders

COO peers & ETF holders

Medical Instruments & SuppliesMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The Cooper Companies reported third‑quarter fiscal 2026 earnings per share of $1.15, surpassing the consensus estimate of $1.11, largely due to effective expense management and a significant tax benefit. GAAP earnings per share rose sharply to $2.24 from $0.49 a year earlier, reflecting the tax benefit. However, revenue increased only 0.6% year over year to $1.066 billion, falling short of the consensus estimate of $1.099 billion by 3.0%. The mixed financial results suggest modest upside momentum but also highlight revenue pressure, indicating a cautious outlook for the next quarter.
What did this article say?
Lawrence Erik Kurzius, a director of The Cooper Companies, increased his direct stake by purchasing 10,000 shares on September 14, 2026, at $53.91 per share. The transaction raised his ownership from 11,099 to 21,099 shares, a 90% increase. The purchase price was slightly below the market close, indicating a favorable entry point. The move follows a 19% decline in the stock over the past year, suggesting the insider believes the company’s turnaround prospects are improving. The acquisition signals confidence in COO’s future performance and may influence investor sentiment.
What did this article say?
On September 11, 2026, Director Paul A. Keel purchased 4,701 shares of The Cooper Companies, Inc. (COO) for a total of $250,000 at $53.18 per share, following a 21% decline over the prior year. The transaction represents the entirety of Keel’s direct holdings and establishes a new cost basis for his equity exposure. The purchase was made at a price slightly above the market close of $53.91, indicating a belief that the stock is undervalued and poised for recovery. This insider buying activity suggests management confidence in the company’s valuation and future prospects.
What did this article say?
Barclays analyst Christopher Pasquale announced new coverage of Cooper Companies (NASDAQ:COO) on October 7, assigning an Equal‑Weight rating. The firm set a price target of $60 per share, signaling a bullish outlook for the company. The coverage launch reflects confidence in COO’s growth prospects and operational performance. This move may influence investor sentiment and trading activity in the near term.
What did this article say?
On September 11 and 14, 2026, Walter M. Jr. Rosebrough, a director of The Cooper Companies, purchased 10,000 shares of COO stock for an average price of $54.16, slightly above the market close. The transaction increased the trust’s holding to 20,000 shares, while the director retained 832 shares personally. The purchase price was marginally higher than the September 15 close of $53.27, indicating a modest confidence in the company’s valuation. The move was disclosed via a Form 4 filing and reflects a routine insider acquisition without immediate impact on the company’s outlook.
What did this article say?
Lawrence Erik Kurzius, a director of The Cooper Companies, Inc., bought 10,000 shares of the company’s common stock on September 16, 2026, for a total of $549,300. The transaction raised his holdings to 31,099 shares, valued at approximately $1.70 million at the closing price that day. COO’s trailing‑12‑month revenue was $4.2 billion with a net income of $570.3 million, indicating solid financial performance. The insider purchase, occurring after a 16 % decline over the past year, suggests management’s confidence in the company’s future trajectory.
What did this article say?
Activist firm Jana Partners disclosed a stake in The Cooper Companies (NASDAQ:COO) and began demanding a CEO and board chair replacement in mid‑September 2026. The pressure follows a 28% drop in the stock since Jana first disclosed its position. Jana cited inventory management and capital allocation issues, threatening a proxy fight if the company does not act before the January nomination deadline. The campaign signals a material negative outlook for COO, as leadership changes could be costly and uncertain.
What did this article say?
Cooper Companies opened its Vision Centre in Southampton, a global hub integrating research, clinical work, pilot manufacturing, and advanced technology to accelerate contact lens product development. The launch coincided with a sharp decline in the company’s share price, falling 23.8% over 30 days and 31.7% year‑to‑date. Management has responded by announcing a larger share‑buyback program and addressing activist investor concerns, signaling a potential shift in risk‑reward dynamics. The company’s valuation is currently viewed as undervalued by analysts, suggesting a possible rebound if the new initiatives materialize. The Vision Centre’s integration aims to shorten time‑to‑market for new products, potentially improving future earnings.
What did this article say?
The Cooper Companies announced a new global innovation hub, The Vision Centre, in Southampton, England, aimed at speeding up contact lens development for its CooperVision unit. Six product advancements, including myopia control and advanced silicone hydrogel lenses, were unveiled with launches scheduled over the next several years. Management highlighted that expanding innovation capabilities will drive future growth and strengthen scientific leadership. The announcement is expected to support organic growth and enhance CooperVision’s competitive position in the contact lens market.
What did this article say?
Cooper Companies completed its strategic review, deciding to keep the CooperSurgical unit and expand its share repurchase program. The company reported modest 1% year‑over‑year revenue growth and a 4% rise in adjusted diluted EPS to $1.15 in Q3 FY25. Management highlighted the decision to retain CooperSurgical as a strategic priority and outlined capital deployment plans to support future growth.

Technical Analysis

Real-time indicators across multiple timeframes

17
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.00B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell23,548,92312.13%$1.93B2026-01-29
BlackRock, Inc.▼ Sell15,029,4537.74%$1.08B2026-08-07
Geode Capital Management, LLC▲ Buy5,359,8122.76%$382.87M2026-08-12
AQR Capital Management LLC▲ Buy4,022,6142.07%$285.69M2026-08-14
Citadel Advisors LLC▲ Buy3,872,3971.99%$277.69M2026-09-02
Invesco Ltd.▲ Buy3,685,0381.90%$264.25M2026-08-14
JANA Partners Management, LP▲ Buy3,582,4801.85%$256.90M2026-08-14
Wellington Management Group LLP▲ Buy3,468,9511.79%$248.76M2026-08-14
Janus Henderson Group plc▼ Sell3,067,1251.58%$219.30M2026-05-18
Bank of America Corp▲ Buy2,009,8351.04%$144.13M2026-08-14
Morgan Stanley▼ Sell1,805,2050.93%$129.45M2026-08-13
Northern Trust Corp▼ Sell1,704,0630.88%$122.20M2026-08-13
Goldman Sachs Group Inc▲ Buy1,494,4950.77%$107.17M2026-08-14
Wells Fargo & Company▼ Sell1,155,6300.60%$82.87M2026-08-14
Balyasny Asset Management L.P.▲ Buy990,4190.51%$71.02M2026-08-14
FMR LLC (Fidelity)▲ Buy933,1970.48%$66.92M2026-08-13
JPMorgan Chase & Co▲ Buy879,4260.45%$63.43M2026-08-12
Harris Associates L P▲ New766,5200.39%$54.97M2026-08-14
Norges Bank▲ Buy730,4270.38%$52.38M2026-08-12
Capital World Investors▼ Sell591,1280.30%$42.39M2026-08-12
Millennium Management LLC▲ Buy505,2080.26%$36.23M2026-08-14
Neuberger Berman Group LLC▼ Sell353,5230.18%$25.35M2026-08-13
Gotham Asset Management, LLC▲ Buy344,4020.18%$24.70M2026-08-14
Marshall Wace, LLP▼ Sell255,9390.13%$18.35M2026-08-13
Citigroup Inc▲ Buy243,3770.13%$17.45M2026-08-03
Q2 2026 flow:8.51M sh bought ($609.76M)12.29M sh sold ($881.22M)net -3.78M sh (−$271.46M)
View full institutional holdings history →
Congressional Trading Activity
5 disclosed trades · ~$40.0K est. traded value · 4 buys, 1 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-052026-07-02
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-292026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-102026-01-12
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-06-09
View full congressional trading history →

Discover More

MRK
Merck & Co., Inc.
$147.16
+3.65%
TMO
Thermo Fisher Scientific Inc.
$675.48
+1.88%
WST
West Pharmaceutical Services, Inc.
$376.22
+1.18%
ZTS
Zoetis Inc.
$75.56
+1.70%
IDXX
IDEXX Laboratories, Inc.
$525.45
+0.99%
ARKG
ARK Genomic Revolution ETF
$48.31
-0.41%
EW
Edwards Lifesciences Corporation
$85.83
+0.66%
GEHC
GE HealthCare Technologies Inc.
$68.17
-0.90%
RMD
ResMed Inc.
$233.93
-0.47%
XBI
SPDR S&P Biotech ETF
$147.02
+0.15%